Technical Perspectives on Generic Drugs Stocks -- Allergan, Catalyst Pharma, Flexion Therapeutics, and Supernus Pharma

Thursday, May 3, 2018 Genetics & Stem Cells News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, May 3, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community. 

Today we are offering reports on AGN, CPRX, FLXN, and SUPN which can be accessed for free by signing up to www.wallstequities.com/registration. Research reports have been issued by WallStEquities.com on Allergan PLC (NYSE: AGN), Catalyst Pharmaceuticals
Inc. (NASDAQ: CPRX), Flexion Therapeutics Inc. (NASDAQ: FLXN), and Supernus Pharmaceuticals Inc. (NASDAQ: SUPN). Generic Drugs Manufacturing companies are capable of selling generic drugs at the lower price, because they are not required to repeat costly clinical trials and pay for marketing and promotion strategies. Patent expiration of branded drugs is one of the key influencers for the growth and prime reason for generating more revenue for generic drugs market. All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Allergan

Shares in Dublin, Ireland headquartered Allergan PLC saw a decline of 1.22%, ending Wednesday's trading session at $151.07. The stock recorded a trading volume of 2.85 million shares. The Company's shares are trading 5.96% below their 50-day moving average. Moreover, shares of Allergan, which develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide, have a Relative Strength Index (RSI) of 37.97.  

On April 24th, 2018, research firm Citigroup resumed its 'Buy' rating on the Company's stock, with a target price of $200 per share.

On May 01st, 2018, Allergan announced that CFO, Matthew Walsh, will present at the Deutsche Bank 43rd Annual Health Care Conference on May 08th, 2018, in Boston, Massachusetts. The presentation will begin at 10:40 a.m. ET. The live webcast of the presentation can be accessed on the Company's Investor Relations website. Get the full research report on AGN for free by clicking below at:

www.wallstequities.com/registration/?symbol=AGN

Catalyst Pharmaceuticals

Coral Gables, Florida-based Catalyst Pharmaceuticals Inc.'s stock closed the day flat at $2.86 with a total trading volume of 514,994 shares. The Company's shares have advanced 26.55% in the past month and 60.67% over the past year. The stock is trading 2.22% above its 50-day moving average. Additionally, shares of Catalyst Pharma, which focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, have an RSI of 57.69. 

On April 19th, 2018, Catalyst Pharma announced that its first patient has been enrolled into its Phase-3 clinical trial (designated as MSK-002) to evaluate the efficacy and safety of Firdapse® (amifampridine phosphate) in patients with MuSK antibody positive Myasthenia Gravis (MuSK-MG). Access the free research report on CPRX now by signing up at:

www.wallstequities.com/registration/?symbol=CPRX

Flexion Therapeutics

On Wednesday, shares in Burlington, Massachusetts headquartered Flexion Therapeutics Inc. recorded a trading volume of 358,742 shares. The stock ended the day 1.74% higher at $25.66. The Company's shares have advanced 4.52% in the past month, 13.59% in the previous three months, and 30.12% over the past year. The stock is trading above its 50-day and 200-day moving averages by 3.07% and 5.66%, respectively. Furthermore, shares of Flexion Therapeutics, which focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions, have an RSI of 53.01.  

On April 30th, 2018, Flexion Therapeutics announced that it will report its Q1 2018 financial results after the close of the US financial markets on May 08th, 2018. Management will host a conference call at 4:30 p.m. ET that same day to discuss the results and provide an update on business operations. A live webcast of the conference call can be accessed under the "Investors" tab of the Company's website. Are you already registered with Wall St. Equities? Do so now for free, and get the report on FLXN at:

www.wallstequities.com/registration/?symbol=FLXN

Supernus Pharmaceuticals

Rockville, Maryland-based Supernus Pharmaceuticals Inc.'s stock declined slightly by 0.21%, finishing yesterday's session at $46.85 with a total trading volume of 467,649 shares. The Company's shares have advanced 3.65% in the last month, 19.97% in the previous three months, and 40.90% over the past year. The stock is trading above its 50-day and 200-day moving averages by 6.10% and 11.69%, respectively. Additionally, shares of Supernus Pharma have an RSI of 55.58.  

On April 24th, 2018, Supernus Pharma announced that it expects to report its financial results for Q1 2018 on May 08th, 2018, after 5:00 p.m. ET. Jack Khattar, President and CEO, and Greg Patrick, CFO, will host a conference call on May 09th, 2018, at 9:00 a.m. ET to discuss the results. Aspiring Member, please take a moment to register below for your free research report on SUPN at:

www.wallstequities.com/registration/?symbol=SUPN

--

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Cision View original content:http://www.prnewswire.com/news-releases/technical-perspectives-on-generic-drugs-stocks----allergan-catalyst-pharma-flexion-therapeutics-and-supernus-pharma-300641930.html

SOURCE Wall St. Equities

Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store